Showing results (211-220 of 588) with videos related to

Sort By:
Pageof 59
Antimicrobial Agents and Chemotherapy|August 22, 2018
Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult SubjectsKeith A Rodvold, Mark H Gotfried, Robin D Isaacs, et al.
Immunotherapy Advances|December 25, 2025
A phase 1 experimental medicine study of anti-CD3 monoclonal antibody in rheumatoid arthritisCatherine A Lawson, Rachel Harry, Bridget Griffiths, et al.
Archives of Disease in Childhood|February 1, 1990
Neonatal pneumoniaS Webber, A R Wilkinson, D Lindsell, et al.
Rheumatology (Oxford, England)|July 5, 2016
Components of treatment delay in rheumatoid arthritis differ according to autoantibody status: validation of a single-centre observation using national audit dataArthur G Pratt, Dennis Lendrem, Ben Hargreaves, et al.
The Journal of Rheumatology|June 1, 1996
Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1HJ D Isaacs, B L Hazleman, K Chakravarty, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 9, 2005
A non-glycosaminoglycan-binding variant of CC chemokine ligand 7 (monocyte chemoattractant protein-3) antagonizes chemokine-mediated inflammationSimi Ali, Helen Robertson, Julie H Wain, et al.
The Medical Journal of Australia|February 20, 1995
Systemic bacterial and fungal infections in infants in Australian neonatal units. Australian Study Group for Neonatal InfectionsD Isaacs, C P Barfield, K Grimwood, et al.
Rheumatology (Oxford, England)|July 24, 2021
Predictors of poor function in RA based on two prospective UK inception cohorts. Do comorbidities matter?Amanda D Busby, James Wason, Arthur G Pratt, et al.
Molecular Endocrinology (Baltimore, Md.)|March 27, 2012
Estrogen regulates JNK1 genomic localization to control gene expression and cell growth in breast cancer cellsMiao Sun, Gary D Isaacs, Nasun Hah, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 14, 2019
Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory DocumentsVibeke Strand, Joao Gonçalves, Timothy P Hickling, et al.
Pageof 59